Thrombosis Research Institute (TRI) to Announce New Real-World Insights in Atrial Fibrillation at ESC Congress 2018

Munich (ots/PRNewswire) -

- Satellite symposium will highlight the breadth of evidence
collected since the establishment of the registry in 2009
- An analysis of the comparative effectiveness of oral anticoagulants
in everyday practice will be presented
- The economic burden of atrial fibrillation (AF) in nine European
countries will be evaluated

The latest results from the Global Anticoagulant Registry in the
Field - Atrial Fibrillation (GARFIELD-AF) will be presented at the
forthcoming ESC Congress 2018, organised by the European Society of
Cardiology, to be held in Munich, Germany, from 25th to 29th August.

Data will be presented as posters, oral presentations and at the
late breaking science session on clinical registries, exploring a
range of areas including the burden attributable to AF in nine
European countries, clinicians' prescribing tendencies, and how the
quality of stroke prevention has changed over time.

The late breaking science session "Registry Results 2" on Tuesday
28th August, 14:30-15:45, (Centre Stage - The Hub) will see
Professors John Camm and Keith Fox present the latest results from
the GARFIELD-AF Registry. Professor Camm will highlight significant
differences in the risk of mortality in favour of OACs (vs. no OAC)
and NOACs (vs. VKAS) even after adjustment for baseline variables.
Professor Fox will present findings that challenge the use of
combined OAC+AP therapy, particularly among those without a clear
indication for AP therapy.

"We are excited to have a strong presence at this year's ESC
Congress, as a result of the wealth of new GARFIELD-AF data, which
will be presented by some of the leading investigators involved in
the registry," said Rt Hon Professor the Lord Ajay K. Kakkar,
Professor of Surgery at University College London and Director of the
Thrombosis Research Institute (TRI), UK.

GARFIELD-AF is the largest ongoing prospective registry of
patients with AF. It is a pioneering, independent outcomes research
initiative led by an international steering committee under the
auspices of the TRI. It has generated at least 2 years of follow-up
data in over 52,000 patients with newly diagnosed AF.

Key results will be unveiled during the TRI Satellite Symposium
which will showcase the wealth of evidence collected since the
establishment of GARFIELD-AF in 2010.

GARFIELD-AF: New light shed on Atrial Fibrillation and its
management

- Satellite Symposium
- Saturday 25th August 2018 from 15.30 - 17.00 (all times CEST) -
Room Vienna - Village 3

Members of the GARFIELD-AF Steering Committee will present a